Nectar Lifesciences is an API manufacturer based in India. It holds 16 active US drug master files across a filed portfolio of 9 molecules. Its filings concentrate with ARCSA (EC), ZAMRA (ZM) and EFDA (ET). Customs aggregates show $43.8M of exports covering 556 molecules to 53 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Tehsil Dera Bassi, India | Not on file |
| SOLAN, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Cefepime | SFDA (Saudi Arabia), US FDA | 4 |
| Ceftriaxone | SFDA (Saudi Arabia), US FDA | 4 |
| Cefuroxime | US FDA | 4 |
| Cefotaxime | SFDA (Saudi Arabia), US FDA | 3 |
| Cefixime | SFDA (Saudi Arabia), US FDA | 2 |
| Cefdinir | US FDA | 1 |
| Cefpodoxime | US FDA | 1 |
| Ceftazidime | US FDA | 1 |
| Cefuroxime Axetil | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 5 | None |
| ZAMRA (ZM) | 5 | None |
| EFDA (ET) | 4 | None |
| TMDA (TZ) | 4 | None |
| INVIMA (CO) | 3 | None |
| MINSA (CR) | 3 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $104K | 2 |
| 2025 | $191.0M | $43.8M | 53 |
| 2024 | $201.0M | $76.3M | 65 |
| 2023 | $184.1M | $86.0M | 61 |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Nectar Lifesciences comes back tiered against every other supplier able to file there.
Start for free